Eyelash enhancement properties of topical dechloro ethylcloprostenolamide

J Cosmet Laser Ther. 2008 Jun;10(2):110-3. doi: 10.1080/14764170802054138.


Objective: To assess subjective reports by users of MD Lash Factor(TM) that it improved the appearance of their eyelashes, especially in length.

Methods: A randomized, double-blind, clinical trial was performed on 34 healthy volunteers who were randomly assigned to one of three different treatment groups of varying concentrations of the key ingredient (dechloro ethylcloprostenolamide, a novel synthetic topical prostaglandin analogue) and a placebo group.

Results: All treatment groups demonstrated a statistically significant increase in eyelash length after 4 weeks of daily use. Group A: 1.69 mm, Group B: 1.94 mm, Group D: 1.44 mm, and Group C (placebo): 0.63 mm. There were no complications. Fifteen patients reported minimal initial transient irritation.

Conclusion: Subjective reports by users of improved appearance in their eyelashes were confirmed. Use of dechloro ethylcloprostenolamide had minimal side effects.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cloprostenol / administration & dosage
  • Cloprostenol / analogs & derivatives*
  • Cloprostenol / therapeutic use
  • Cosmetics / administration & dosage
  • Cosmetics / therapeutic use*
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Eyelashes / drug effects*
  • Female
  • Humans
  • Male
  • Middle Aged


  • Cosmetics
  • Cloprostenol
  • dechloro ethylcloprostenolamide